Metal-organic Frameworks As Nanoplatforms for Combination Therapy in Cancer Treatment

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 9

PMID 39653960

Authors

Zainab Lafi

Sina Matalqah

Ebaa Abu-Saleem

Nisreen Asha

Hala Mhaidat

Sherine Asha

Lara Al-Nashash

Hussein S Janabi

Affiliations

Soon will be listed here.

Abstract

The integration of nanotechnology into cancer treatment has revolutionized chemotherapy, boosted its effectiveness while reduced side effects. Among the various nanotherapeutic approaches, metal-organic frameworks (MOFs) stand out as promising carriers for targeted chemotherapy, with the added benefit of enabling combination therapies. MOFs, composed of metal ions or clusters linked by coordination bonds, tackle critical issues in traditional cancer treatments, such as poor stability, limited efficacy, and severe side effects. Their key advantages include customizable size and shape, diverse compositions, controlled porosity, large surface areas, ease of modification, and biocompatibility. This review highlights recent advancements in the use of MOFs for cancer therapy, showcasing their role in both monotherapies and combination strategies. Additionally, it explores the future potential and challenges of MOF-based platforms in tumor treatment.

Citing Articles

Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.

Abu Saleem E, Lafi Z, Shalan N, Alshaer W, Hamadneh I Nanomedicine (Lond). 2025; 20(5):467-479.

PMID: 39888613 PMC: 11875491. DOI: 10.1080/17435889.2025.2459059.

References

Bazeed A, Day C, Garg S . Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies. Cancers (Basel). 2022; 14(17). PMC: 9454856. DOI: 10.3390/cancers14174257. View

Zeng S, Pottler M, Lan B, Grutzmann R, Pilarsky C, Yang H . Chemoresistance in Pancreatic Cancer. Int J Mol Sci. 2019; 20(18). PMC: 6770382. DOI: 10.3390/ijms20184504. View

Alshaer W, Zraikat M, Amer A, Nsairat H, Lafi Z, Alqudah D . Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes: anti-proliferative and anti-invasive activity in glioblastoma. RSC Adv. 2022; 9(53):30976-30988. PMC: 9072562. DOI: 10.1039/c9ra05636j. View

Lafi Z, Alshaer W, Gharaibeh L, Alqudah D, AlQuaissi B, Bashaireh B . Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line. PLoS One. 2023; 18(9):e0291981. PMC: 10538757. DOI: 10.1371/journal.pone.0291981. View

Al-Harbi S, Almulaiky Y . Copper-based metal-organic frameworks (BDC-Cu MOFs) as supporters for α-amylase: Stability, reusability, and antioxidant potential. Heliyon. 2024; 10(6):e28396. PMC: 10979214. DOI: 10.1016/j.heliyon.2024.e28396. View

Shano L, Karthikeyan S, Kennedy L, Chinnathambi S, Pandian G . MOFs for next-generation cancer therapeutics through a biophysical approach-a review. Front Bioeng Biotechnol. 2024; 12:1397804. PMC: 11208718. DOI: 10.3389/fbioe.2024.1397804. View

Liu Y, Wu Y, Luo Z, Li M . Designing supramolecular self-assembly nanomaterials as stimuli-responsive drug delivery platforms for cancer therapy. iScience. 2023; 26(3):106279. PMC: 10014307. DOI: 10.1016/j.isci.2023.106279. View

Letwaba J, Uyor U, Mavhungu M, Achuka N, Popoola P . A review on MOFs synthesis and effect of their structural characteristics for hydrogen adsorption. RSC Adv. 2024; 14(20):14233-14253. PMC: 11058478. DOI: 10.1039/d4ra00865k. View

10.

Yusuf V, Malek N, Kailasa S . Review on Metal-Organic Framework Classification, Synthetic Approaches, and Influencing Factors: Applications in Energy, Drug Delivery, and Wastewater Treatment. ACS Omega. 2022; 7(49):44507-44531. PMC: 9753116. DOI: 10.1021/acsomega.2c05310. View

11.

Challa M, Chinnam S, Rajanna A, Nandagudi A, Yallur B, Adimule V . Adsorption efficacy of functionalized Cu-BDC MOFs tethered 2-mercaptobenzimidazole analogue: A comparative study. Heliyon. 2023; 9(2):e13223. PMC: 9922976. DOI: 10.1016/j.heliyon.2023.e13223. View

13.

Chen G, Luo J, Cai M, Qin L, Wang Y, Gao L . Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier. Molecules. 2019; 24(18). PMC: 6767262. DOI: 10.3390/molecules24183369. View

14.

Rezaeipour Y, Zolghadr E, Alizadeh P, Sadri G, Wujcik E, Afkhami F . The anticancer properties of metal-organic frameworks and their heterogeneous nanocomposites. Biomater Adv. 2022; 139:213013. DOI: 10.1016/j.bioadv.2022.213013. View

15.

Alneghery L, Al-Zharani M, Nasr F, Eldin Z, Al Hujran T, Tawfeek H . Fabrication and optimization of naringin-loaded MOF-5 encapsulated by liponiosomes as smart drug delivery, cytotoxicity, and apoptotic on breast cancer cells. Drug Dev Ind Pharm. 2024; :1-14. DOI: 10.1080/03639045.2024.2388786. View

16.

Zelenka T, Balaz M, Ferova M, Diko P, Bednarcik J, Kiralyova A . The influence of HKUST-1 and MOF-76 hand grinding/mechanical activation on stability, particle size, textural properties and carbon dioxide sorption. Sci Rep. 2024; 14(1):15386. PMC: 11224341. DOI: 10.1038/s41598-024-66432-z. View

17.

Shen J, Zhou W, Jia M, Yang X, Lin J, An L . Tumor Microenvironment-Responsive Reagent DFS@HKUST-1 for Photoacoustic Imaging-Guided Multimethod Therapy. ACS Appl Bio Mater. 2022; 4(7):5753-5764. DOI: 10.1021/acsabm.1c00521. View

18.

Boroushaki T, Ganjali Koli M, Malekshah R, Dekamin M . Elucidating anticancer drugs release from UiO-66 as a carrier through the computational approaches. RSC Adv. 2023; 13(45):31897-31907. PMC: 10618728. DOI: 10.1039/d3ra05587f. View

19.

Wang J, Chen D, Li B, He J, Duan D, Shao D . Fe-MIL-101 exhibits selective cytotoxicity and inhibition of angiogenesis in ovarian cancer cells via downregulation of MMP. Sci Rep. 2016; 6:26126. PMC: 4870622. DOI: 10.1038/srep26126. View

20.

Alavijeh R, Akhbari K . Biocompatible MIL-101(Fe) as a Smart Carrier with High Loading Potential and Sustained Release of Curcumin. Inorg Chem. 2020; 59(6):3570-3578. DOI: 10.1021/acs.inorgchem.9b02756. View

21.

Sun M, Wang L, Zhuo Y, Xu S, Liu H, Jiang X . Multi-Enzyme Activity of MIL-101 (Fe)-Derived Cascade Nano-Enzymes for Antitumor and Antimicrobial Therapy. Small. 2023; 20(17):e2309593. DOI: 10.1002/smll.202309593. View

22.

Wang Q, Sun Y, Li S, Zhang P, Yao Q . Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy. RSC Adv. 2022; 10(62):37600-37620. PMC: 9057214. DOI: 10.1039/d0ra07950b. View